Immunotherapy of malignant tumors in the brain: How different from other sites?

Frontiers in Oncology

Valérie Dutoit¹  Paul Richard Walker¹  Denis Migliorini¹  Pierre-Yves Dietrich¹ 

[1] Geneva University Hospitals and University of Geneva;

关键词: Glioma;    Tumor Microenvironment;    brain tumors;    Tumor immunotherapy;    Brain homing;   

DOI  :  10.3389/fonc.2016.00256

来源: DOAJ

【 摘 要 】

Immunotherapy is now advancing at remarkable pace for tumors located in various tissues, including the brain. Strategies launched decades ago, such as tumor antigen-specific therapeutic vaccines and adoptive transfer of tumor-infiltrating lymphocytes, are being complemented by molecular engineering approaches allowing the development of tumor-specific TCR transgenic and chimeric antigen receptor T cells. In addition, the spectacular results obtained in the last years with immune checkpoint inhibitors are transfiguring immunotherapy, these agents being used both as single molecules, but also in combination with other immunotherapeutic modalities. Implementation of these various strategies is ongoing for more and more malignancies, including tumors located in the brain, raising the question of the immunological particularities of this site. This may necessitate cautious selection of tumor antigens, minimizing the immunosuppressive environment, and promoting efficient T cell trafficking to the tumor. Once these aspects are taken into account, we might efficiently design immunotherapy for patients suffering from tumors located in the brain, with beneficial clinical outcome.

【 授权许可】

Unknown